Intraperitoneal photodynamic therapy

Peritoneal Carcinomatosis: A Multidisciplinary Approach

Volumn , Issue , 2007, Pages 493-514

  Cengel, Keith A ^a   Glatstein, Eli ^a   Hahn, Stephen M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; APOPTOSIS; CLINICAL TRIAL; HUMAN; METHODOLOGY; MOUSE; PERITONEUM; PERITONEUM TUMOR; PHOTOCHEMOTHERAPY; RABBIT; REVIEW;

ANIMALS; APOPTOSIS; CLINICAL TRIALS; HUMANS; MICE; PERITONEAL NEOPLASMS; PERITONEUM; PHOTOCHEMOTHERAPY; RABBITS;

EID: 79954466728     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-48993-3_34     Document Type: Chapter

References (120)

1. Dougherty TJ, Grindey GB, Fiel R, Weishaupt KR and Boyle DG (1975) Photoradiation therapy. II. Cure of animal tumours with hematoporphyrin and light. J Natl Cancer Inst 55:115-121
2. Manyak MJ, Russo A, Smith PD and Glatstein E (1988) Photodynamic therapy. J Clin Oncol 6:380-391
3. Weishaupt KR, Gomer CJ and Dougherty TJ (1976) Identification of singlet oxygen as the cytotoxic agent in photoinactivation of a murine tumour. Cancer Res 36:2326-2329
4. Peng Q and Nesland JM (2004) Effects of photodynamic therapy on tumour stroma. Ultrastruct Pathol 28:333-340
5. Nelson JS, Liaw LH, Orenstein A, Roberts WG and Berns MW (1988) Mechanism of tumour destruction following photodynamic therapy with hematoporphyrin derivative, chlorin, and phthalocyanine. J Natl Cancer Inst 80:1599-1605
6. van Duijnhoven FH, Aalbers RI, Rovers JP, Terpstra OT and Kuppen PJ (2003) The immunological consequences of photodynamic treatment of cancer, a literature review. Immunobiology 207:105-113
7. Almeida RD, Manadas BJ, Carvalho AP and Duarte CB (2004) Intracellular signaling mechanisms in photodynamic therapy. Biochim Biophys Acta 1704:59-86
8. Biel MA (1994) Photodynamic therapy and the treatment of neoplastic diseases of the larynx. Laryngoscope 104:399-403
9. D'Cruz AK, Robinson MH and Biel MA (2004) mTHPC-mediated photodynamic therapy in patients with advanced, incurable head and neck cancer: a multicenter study of 128 patients. Head Neck 26:232-240
10. Wenig BL, Kurtzman DM, Grossweiner LI, Mafee MF, Harris DM, Lobraico RV, Prycz RA and Appelbaum EL (1990) Photodynamic therapy in the treatment of squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 116:1267-1270
11. Cortese DA, Edell ES and Kinsey JH (1997) Photodynamic therapy for early stage squamous cell carcinoma of the lung. Mayo Clin Proc 72:595-602
12. Diaz-Jimenez JP, Martinez-Ballarin JE, Llunell A, Farrero E, Rodriguez A and Castro MJ (1999) Efficacy and safety of photodynamic therapy versus Nd-YAG laser resection in NSCLC with airway obstruction. Eur Respir J 14:800-805
13. Furuse K, Fukuoka M, Kato H, Horai T, Kubota K, Kodama N, Kusunoki Y, Takifuji N, Okunaka T, Konaka C et al (1993) A prospective phase II study on photodynamic therapy with photofrin II for centrally located early-stage lung cancer. The Japan Lung Cancer Photodynamic Therapy Study Group. J Clin Oncol 11:1852-1857
14. Friedberg JS, Mick R, Stevenson JP, Zhu T, Busch TM, Shin D, Smith D, Culligan M, Dimofte A, Glatstein E and Hahn SM (2004) Phase II trial of pleural photodynamic therapy and surgery for patients with non-small-cell lung cancer with pleural spread. J Clin Oncol 22:2192-2201
15. Baas P, Murrer L, Zoetmulder FA, Stewart FA, Ris HB, van Zandwijk N, Peterse JL and Rutgers EJ (1997) Photodynamic therapy as adjuvant therapy in surgically treated pleural malignancies. Br J Cancer 76:819-826
16. Hahn SM, Smith RP and Friedberg J (2001) Photodynamic therapy for mesothelioma. Curr Treat Options Oncol 2:375-383
17. Pass HI, DeLaney TF, Tochner Z, Smith PE, Temeck BK, Pogrebniak HW, Kranda KC, Russo A, Friauf WS, Cole JW et al (1994) Intrapleural photodynamic therapy: results of a phase I trial. Ann Surg Oncol 1:28-37
18. Lightdale CJ, Heier SK, Marcon NE, McCaughan JS, Jr., Gerdes H, Overholt BF, Sivak MV, Jr., Stiegmann GV and Nava HR (1995) Photodynamic therapy with porfimer sodium versus thermal ablation therapy with Nd:YAG laser for palliation of esophageal cancer: a multicenter randomized trial. Gastrointest Endosc 42:507-512
19. Kelley DJ and Shah JP (1996) Management of Barrett's oesophagus. Lancet 348:561-562
20. Overholt BF, Lightdale CJ, Wang KK, Canto MI, Burdick S, Haggitt RC, Bronner MP, Taylor SL, Grace MG and Depot M (2005) Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial. Gastrointest Endosc 62:488-498
21. Ortner ME, Caca K, Berr F, Liebetruth J, Mansmann U, Huster D, Voderholzer W, Schachschal G, Mossner J and Lochs H (2003) Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology 125:1355-1363
22. Zoepf T, Jakobs R, Arnold JC, Apel D and Riemann JF (2005) Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy. Am J Gastroenterol 100:2426-2430
23. Muller PJ and Wilson BC (1987) Photodynamic therapy of malignant primary brain tumours: clinical effects, post-operative ICP, and light penetration of the brain. Photochem Photobiol 46:929-935
24. Schuh M, Nseyo UO, Potter WR, Dao TL and Dougherty TJ (1987) Photodynamic therapy for palliation of locally recurrent breast carcinoma. J Clin Oncol 5:1766-1770
25. Sperduto PW, DeLaney TF, Thomas G, Smith P, Dachowski LJ, Russo A, Bonner R and Glatstein E (1991) Photodynamic therapy for chest wall recurrence in breast cancer. Int J Radiat Oncol Biol Phys 21:441-446
26. Marijnissen JP, Star WM, in 't Zandt HJ, D'Hallewin MA and Baert L (1993) In situ light dosimetry during whole bladder wall photodynamic therapy: clinical results and experimental verification. Phys Med Biol 38:567-582
27. Keefe KA, Tadir Y, Tromberg B, Berns M, Osann K, Hashad R and Monk BJ (2002) Photodynamic therapy of high-grade cervical intraepithelial neoplasia with 5-aminolevulinic acid. Lasers Surg Med 31:289-293
28. Barnett AA, Haller JC, Cairnduff F, Lane G, Brown SB and Roberts DJ (2003) A randomised, double-blind, placebo-controlled trial of photodynamic therapy using 5-aminolaevulinic acid for the treatment of cervical intraepithelial neoplasia. Int J Cancer 103:829-832
29. Verigos K, Stripp DC, Mick R, Zhu TC, Whittington R, Smith D, Dimofte A, Finlay J, Busch TM, Tochner ZA, Malkowicz S, Glatstein E and Hahn SM (2006) Updated results of a phase I trial of motexafin lutetium-mediated interstitial photodynamic therapy in patients with locally recurrent prostate cancer. J Environ Pathol Toxicol Oncol 25:373-388
30. Zhu TC, Dimofte A, Finlay JC, Stripp D, Busch T, Miles J, Whittington R, Malkowicz SB, Tochner Z, Glatstein E and Hahn SM (2005) Optical properties of human prostate at 732 nm measured in mediated photodynamic therapy. Photochem Photobiol 81:96-105
31. Zhu TC, Hahn SM, Kapatkin AS, Dimofte A, Rodriguez CE, Vulcan TG, Glatstein E and Hsi RA (2003) In vivo optical properties of normal canine prostate at 732 nm using motexafin lutetium-mediated photodynamic therapy. Photochem Photobiol 77:81-88
32. Morton C, Horn M, Leman J, Tack B, Bedane C, Tjioe M, Ibbotson S, Khemis A and Wolf P (2006) Comparison of topical methyl aminolevulinate photodynamic therapy with cryotherapy or Fluorouracil for treatment of squamous cell carcinoma in situ: Results of a multicenter randomized trial. Arch Dermatol 142:729-735
33. Lui H, Hobbs L, Tope WD, Lee PK, Elmets C, Provost N, Chan A, Neyndorff H, Su XY, Jain H, Hamzavi I, McLean D and Bissonnette R (2004) Photodynamic therapy of multiple nonmelanoma skin cancers with verteporfin and red light-emitting diodes: two-year results evaluating tumour response and cosmetic outcomes. Arch Dermatol 140:26-32
34. Rhodes LE, de Rie M, Enstrom Y, Groves R, Morken T, Goulden V, Wong GA, Grob JJ, Varma S and Wolf P (2004) Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma: results of a multicenter randomized prospective trial. Arch Dermatol 140:17-23
35. Gomer CJ and Dougherty TJ (1979) Determination of [3H]- and [14C] hematoporphyrin derivative distribution in malignant and normal tissue. Cancer Res 39:146-151
36. Young SW, Woodburn KW, Wright M, Mody TD, Fan Q, Sessler JL, Dow WC and Miller RA (1996) Lutetium texaphyrin (PCI-0123): a near-infrared, water-soluble photosensitizer. Photochem Photobiol 63:892-897
37. Hahn S, Putt M, Metz J, Shin D, Rickter E, Menon C, Smith D, Glatstein E, Fraker D and Busch T (2006) Photofrin uptake in the tumour and normal tissues of patients receiving intra-peritoneal photodynamic therapy. Clin Cancer Res, submitted
38. Hahn SM, Fraker DL, Mick R, Metz J, Busch TM, Smith D, Zhu T, Rodriguez C, Dimofte A, Spitz F, Putt M, Rubin SC, Menon C, Wang HW, Shin D, Yodh A and Glatstein E (2006) A phase II trial of intraperitoneal photodynamic therapy for patients with peritoneal carcinomatosis and sarcomatosis. Clin Cancer Res 12:2517-2525
39. Roy I, Ohulchanskyy TY, Pudavar HE, Bergey EJ, Oseroff AR, Morgan J, Dougherty TJ and Prasad PN (2003) Ceramic-based nanoparticles entrapping water-insoluble photosensitizing anticancer drugs: a novel drug-carrier system for photodynamic therapy. J Am Chem Soc 125:7860-7865
40. Oleinick NL, Antunez AR, Clay ME, Rihter BD and Kenney ME (1993) New phthalocyanine photosensitizers for photodynamic therapy. Photochem Photobiol 57:242-247
41. Dolmans DE, Fukumura D and Jain RK (2003) Photodynamic therapy for cancer. Nat Rev Cancer 3:380-387
42. Abels C (2004) Targeting of the vascular system of solid tumours by photodynamic therapy (PDT). Photochem Photobiol Sci 3:765-771
43. Busch TM, Hahn SM, Evans SM and Koch CJ (2000) Depletion of tumour oxygenation during photodynamic therapy: detection by the hypoxia marker EF3 [2-(2-nitroimidazol-1[H]-yl)-N-(3,3,3-trifluoropropyl)acetamide]. Cancer Res 60:2636-2642
44. Busch TM, Hahn SM, Wileyto EP, Koch CJ, Fraker DL, Zhang P, Putt M, Gleason K, Shin DB, Emanuele MJ, Jenkins K, Glatstein E and Evans SM (2004) Hypoxia and photofrin uptake in the intraperitoneal carcinomatosis and sarcomatosis of photodynamic therapy patients. Clin Cancer Res 10:4630-4638
45. Busch TM, Wileyto EP, Emanuele MJ, Del Piero F, Marconato L, Glatstein E and Koch CJ (2002) Photodynamic therapy creates fluence rate-dependent gradients in the intratumoural spatial distribution of oxygen. Cancer Res 62:7273-7279
46. Gollnick SO, Lee BY, Vaughan L, Owczarczak B and Henderson BW (2001) Activation of the IL-10 gene promoter following photodynamic therapy of murine keratinocytes. Photochem Photobiol 73:170-177
47. Gollnick SO, Liu X, Owczarczak B, Musser DA and Henderson BW (1997) Altered expression of interleukin 6 and interleukin 10 as a result of photodynamic therapy in vivo. Cancer Res 57:3904-3909
48. Gollnick SO, Musser DA, Oseroff AR, Vaughan L, Owczarczak B and Henderson BW( 2001) IL-10 does not play a role in cutaneous Photofrin photodynamic therapy-induced suppression of the contact hypersensitivity response. Photochem Photobiol 74:811-816
49. Korbelik M (1996) Induction of tumour immunity by photodynamic therapy. J Clin Laser Med Surg 14:329-334
50. Korbelik M and Cecic I (1999) Contribution of myeloid and lymphoid host cells to the curative outcome of mouse sarcoma treatment by photodynamic therapy. Cancer Lett 137:91-98
51. Korbelik M and Dougherty GJ (1999) Photodynamic therapy-mediated immune response against subcutaneous mouse tumours. Cancer Res 59:1941-1946
52. Cecic I, Sun J and Korbelik M (2006) Role of complement anaphylatoxin C3a in photodynamic therapy-elicited engagement of host neutrophils and other immune cells. Photochem Photobiol 82:558-562
53. Edinger AL and Thompson CB (2004) Death by design: apoptosis, necrosis and autophagy. Curr Opin Cell Biol 16:663-669
54. Korbelik M, Krosl G, Krosl J and Dougherty GJ (1996) The role of host lymphoid populations in the response of mouse EMT6 tumour to photodynamic therapy. Cancer Res 56:5647-5652
55. Luo Y and Kessel D (1997) Initiation of apoptosis versus necrosis by photodynamic therapy with chloroaluminum phthalocyanine. Photochem Photobiol 66:479-483
56. Vantieghem A, Assefa Z, Vandenabeele P, Declercq W, Courtois S, Vandenheede JR, Merlevede W, de Witte P and Agostinis P (1998) Hypericin-induced photosensitization of HeLa cells leads to apoptosis or necrosis. Involvement of cytochrome c and procaspase-3 activation in the mechanism of apoptosis. FEBS Lett 440:19-24
57. Kamuhabwa AR, Agostinis PM, D'Hallewin MA, Baert L and de Witte PA (2001) Cellular photodestruction induced by hypericin in AY-27 rat bladder carcinoma cells. Photochem Photobiol 74:126-132
58. Wyld L, Reed MW and Brown NJ (2001) Differential cell death response to photodynamic therapy is dependent on dose and cell type. Br J Cancer 84:1384-1386
59. Oleinick NL, Morris RL and Belichenko I (2002) The role of apoptosis in response to photodynamic therapy: what, where, why, and how. Photochem Photobiol Sci 1:1-21
60. Murant RS, Gibson SL and Hilf R (1987) Photosensitizing effects of Photofrin II on the site-selected mitochondrial enzymes adenylate kinase and monoamine oxidase. Cancer Res 47:4323-4328
61. Woodburn KW, Vardaxis NJ, Hill JS, Kaye AH and Phillips DR (1991) Subcellular localization of porphyrins using confocal laser scanning microscopy. Photochem Photobiol 54:725-732
62. Ricchelli F, Gobbo S, Jori G, Salet C and Moreno G (1995) Temperature-induced changes in fluorescence properties as a probe of porphyrin microenvironment in lipid membranes. 2. The partition of hematoporphyrin and protoporphyrin in mitochondria. Eur J Biochem 233:165-170
63. Peng Q, Moan J and Nesland JM (1996) Correlation of subcellular and intratumoural photosensitizer localization with ultrastructural features after photodynamic therapy. Ultrastruct Pathol 20:109-129
64. Granville DJ, Levy JG and Hunt DW (1997) Photodynamic therapy induces caspase-3 activation in HL-60 cells. Cell Death Differ 4:623-628
65. Granville DJ, Jiang H, An MT, Levy JG, McManus BM and Hunt DW (1998) Overexpression of Bcl-X(L) prevents caspase-3-mediated activation of DNA fragmentation factor (DFF) produced by treatment with the photochemotherapeutic agent BPD-MA. FEBS Lett 422:151-154
66. Carthy CM, Granville DJ, Jiang H, Levy JG, Rudin CM, Thompson CB, McManus BM and Hunt DW (1999) Early release of mitochondrial cytochrome c and expression of mitochondrial epitope 7A6 with a porphyrinderived photosensitizer: Bcl-2 and Bcl-xL overexpression do not prevent early mitochondrial events but still depress caspase activity. Lab Invest 79:953-965
67. Granville DJ, Jiang H, An MT, Levy JG, McManus BM and Hunt DW (1999) Bcl-2 overexpression blocks caspase activation and downstream apoptotic events instigated by photodynamic therapy. Br J Cancer 79:95-100
68. Granville DJ, Carthy CM, Jiang H, Levy JG, McManus BM, Matroule JY, Piette J and Hunt DW (2000) Nuclear factor-kappaB activation by the photochemotherapeutic agent verteporfin. Blood 95:256-262
69. Dahle J, Bagdonas S, Kaalhus O, Olsen G, Steen HB and Moan J (2000) The bystander effect in photodynamic inactivation of cells. Biochim Biophys Acta 1475:273-280
70. Dahle J, Kaalhus O, Moan J and Steen HB (1997) Cooperative effects of photodynamic treatment of cells in microcolonies. Proc Natl Acad Sci U S A 94:1773-1778
71. Dahle J, Mikalsen SO, Rivedal E and Steen HB (2000) Gap junctional intercellular communication is not a major mediator in the bystander effect in photodynamic treatment of MDCK II cells. Radiat Res 154:331-341
72. Dahle J, Steen HB and Moan J (1999) The mode of cell death induced by photodynamic treatment depends on cell density. Photochem Photobiol 70:363-367
73. Douglass HO, Jr., Nava HR, Weishaupt KR, Boyle D, Sugerman MG, Halpern E and Dougherty TJ (1983) Intra-abdominal applications of hematoporphyrin photoradiation therapy. Adv Exp Med Biol 160:15-21
74. Tochner Z, Mitchell JB, Harrington FS, Smith P, Russo DT and Russo A (1985) Treatment of murine intraperitoneal ovarian ascitic tumour with hematoporphyrin derivative and laser light. Cancer Res 45:2983-2987
75. Ozols RF, Locker GY, Doroshow JH, Grotzinger KR, Myers CE, Fisher RI and Young RC (1979) Chemotherapy for murine ovarian cancer: a rationale for ip therapy with adriamycin. Cancer Treat Rep 63:269-273
76. Tochner Z, Mitchell JB, Smith P, Harrington F, Glatstein E, Russo D and Russo A (1986) Photodynamic therapy of ascites tumours within the peritoneal cavity. Br J Cancer 53:733-736
77. DeLaney TF, Sindelar WF, Tochner Z, Smith PD, Friauf WS, Thomas G, Dachowski L, Cole JW, Steinberg SM and Glatstein E (1993) Phase I study of debulking surgery and photodynamic therapy for disseminated intraperitoneal tumours. Int J Radiat Oncol Biol Phys 25:445-457
78. Sindelar W, Sullivan F, Abraham E, DeLaney T, Smith P, Friauf W, Thomas G, Smith J and Okunieff P (1995) Intraperitoneal Photodynamic Therapy shows efficacy in Phase I Trial. Proc Am Soc Clin Oncol 14:447
79. Sindelar WF, DeLaney TF, Tochner Z, Thomas GF, Dachoswki LJ, Smith PD, Friauf WS, Cole JW and Glatstein E (1991) Technique of photodynamic therapy for disseminated intraperitoneal malignant neoplasms. Phase I study. Arch Surg 126:318-324
80. Selman SH, Kreimer-Birnbaum M, Goldblatt PJ, Anderson TS, Keck RW and Britton SL (1985) Jejunal blood flow after exposure to light in rats injected with hematoporphyrin derivative. Cancer Res 45:6425-6427
81. Suzuki S, Nakamura S and Sakaguchi S (1987) Experimental study of intraabdominal photodynamic therapy. Lasers Med Sci 2:195-203
82. Veenhuizen RB, Ruevekamp-Helmers MC, Helmerhorst TJ, Kenemans P, Mooi WJ, Marijnissen JP and Stewart FA (1994) Intraperitoneal photodynamic therapy in the rat: comparison of toxicity profiles for photofrin and MTHPC. Int J Cancer 59:830-836
83. Tochner Z, Mitchell JB, Hoekstra HJ, Smith P, DeLuca AM, Barnes M, Harrington F, Manyak M, Russo D, Russo A et al (1991) Photodynamic therapy of the canine peritoneum: normal tissue response to intraperitoneal and intravenous photofrin followed by 630 nm light. Lasers Surg Med 11:158-164
84. DeLaney TF, Sindelar WF, Thomas GF, DeLuca AM and Taubenberger JK (1993) Tolerance of small bowel anastomoses in rabbits to photodynamic therapy with dihematoporphyrin ethers and 630 nm red light. Lasers Surg Med 13:664-671
85. Veenhuizen RB, Marijnissen JP, Kenemans P, Ruevekamp-Helmers MC, t Mannetje LW, Helmerhorst TJ and Stewart FA (1996) Intraperitoneal photodynamic therapy of the rat CC531 adenocarcinoma. Br J Cancer 73:1387-1392
86. Molpus KL, Kato D, Hamblin MR, Lilge L, Bamberg M and Hasan T (1996) Intraperitoneal photodynamic therapy of human epithelial ovarian carcinomatosis in a xenograft murine model. Cancer Res 56:1075-1082
87. 3. Opt Lett 25:338
88. Major AL, Rose GS, Chapman CF, Hiserodt JC, Tromberg BJ, Krasieva TB, Tadir Y, Haller U, DiSaia PJ and Berns MW (1997) In vivo fluorescence detection of ovarian cancer in the NuTu-19 epithelial ovarian cancer animal model using 5-aminolevulinic acid (ALA). Gynecol Oncol 66:122-132
89. Loning MC, Diddens HC, Holl-Ulrich K, Loning U, Kupker W, Diedrich K and Huttmann G (2006) Fluorescence staining of human ovarian cancer tissue following application of 5-aminolevulinic acid: Fluorescence microscopy studies. Lasers Surg Med 38:549-554
90. Major AL, Rose GS, Svaasand LO, Ludicke F, Campana A and van Gemert MJ (2002) Intraperitoneal photodynamic therapy in the Fischer 344 rat using 5-aminolevulinic acid and violet laser light: a toxicity study. J Photochem Photobiol B 66:107-114
91. Li G, Szewczuk MR, Pottier RH and Kennedy JC (1999) Effect of mammalian cell differentiation on response to exogenous 5-aminolevulinic acid. Photochem Photobiol 69:231-235
92. Ortel B, Chen N, Brissette J, Dotto GP, Maytin E and Hasan T (1998) Differentiation-specific increase in ALA-induced protoporphyrin IX accumulation in primary mouse keratinocytes. Br J Cancer 77:1744-1751
93. Ortel B, Sharlin D, O'Donnell D, Sinha AK, Maytin EV and Hasan T (2002) Differentiation enhances aminolevulinic acid-dependent photodynamic treatment of LNCaP prostate cancer cells. Br J Cancer 87:1321-1327
94. Griffin GM, Zhu T, Solonenko M, Del Piero F, Kapakin A, Busch TM, Yodh A, Polin G, Bauer T, Fraker D and Hahn SM (2001) Preclinical evaluation of motexafin lutetium-mediated intraperitoneal photodynamic therapy in a canine model. Clin Cancer Res 7:374-381
95. Ross HM, Smelstoys JA, Davis GJ, Kapatkin AS, Del Piero F, Reineke E, Wang H, Zhu TC, Busch TM, Yodh AG and Hahn SM (2006) Photodynamic Therapy with Motexafin Lutetium for Rectal Cancer: A Preclinical Model in the Dog. J Surg Res, in press
96. Wilson JJ, Jones H, Burock M, Smith D, Fraker DL, Metz J, Glatstein E and Hahn SM (2004) Patterns of recurrence in patients treated with photodynamic therapy for intraperitoneal carcinomatosis and sarcomatosis. Int J Oncol 24:711-717
97. Hendren SK, Hahn SM, Spitz FR, Bauer TW, Rubin SC, Zhu T, Glatstein E and Fraker DL (2001) Phase II trial of debulking surgery and photodynamic therapy for disseminated intraperitoneal tumours. Ann Surg Oncol 8:65-71
98. Canter RJ, Mick R, Kesmodel SB, Raz DJ, Spitz FR, Metz JM, Glatstein EJ, Hahn SM and Fraker DL (2003) Intraperitoneal photodynamic therapy causes a capillary-leak syndrome. Ann Surg Oncol 10:514-524
99. Menon C, Kutney SN, Lehr SC, Hendren SK, Busch TM, Hahn SM and Fraker DL (2001) Vascularity and uptake of photosensitizer in small human tumour nodules: implications for intraperitoneal photodynamic therapy. Clin Cancer Res 7:3904-3911
100. Bauer TW, Hahn SM, Spitz FR, Kachur A, Glatstein E and Fraker DL (2001) Preliminary report of photodynamic therapy for intraperitoneal sarcomatosis. Ann Surg Oncol 8:254-259
101. Dimofte A, Zhu TC, Hahn SM and Lustig RA (2002) In vivo light dosimetry for motexafin lutetium-mediated PDT of recurrent breast cancer. Lasers Surg Med 31:305-312
102. Wang HW, Zhu TC, Putt ME, Solonenko M, Metz J, Dimofte A, Miles J, Fraker DL, Glatstein E, Hahn SM and Yodh AG (2005) Broadband reflectance measurements of light penetration, blood oxygenation, hemoglobin concentration, and drug concentration in human intraperitoneal tissues before and after photodynamic therapy. J Biomed Opt 10:14004.
103. Van Staveren H, Marijnissen J, Aalders M and Star W (1995) Construction, quality control and calibration of spherical isotropic fibre-optic light diffusers. Lasers Med Sci 10:137-147
104. Vulcan TG, Zhu TC, Rodriguez CE, Hsi A, Fraker DL, Baas P, Murrer LH, Star WM, Glatstein E, Yodh AG and Hahn SM (2000) Comparison between isotropic and nonisotropic dosimetry systems during intraperitoneal photodynamic therapy. Lasers Surg Med 26:292-301
105. Wang HW, Putt ME, Emanuele MJ, Shin DB, Glatstein E, Yodh AG and Busch TM (2004) Treatment-induced changes in tumour oxygenation predict photodynamic therapy outcome. Cancer Res 64:7553-7561
106. Silva CM (2004) Role of STATs as downstream signal transducers in Src family kinase-mediated tumourigenesis. Oncogene 23:8017-8023
107. Hynes NE and Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5:341-354
108. Fanuel-Barret D, Patrice T, Foultier MT, Vonarx-Coinsmann V, Robillard N and Lajat Y (1997) Influence of epidermal growth factor on photodynamic therapy of glioblastoma cells in vitro. Res Exp Med (Berl) 197:219-233
109. Tong Z, Singh G and Rainbow AJ (2002) Sustained activation of the extracellular signal-regulated kinase pathway protects cells from photofrin-mediated photodynamic therapy. Cancer Res 62:5528-5535
110. Moor A, Rizvi I, Savellano M, Yu W, Del Carmen M and Hasan T (2000) Photoimunotargeting of the epidermal growth factor receptor for the treatment of ovarian cancer. 13th International Congress on Photobiology and 28th Annual Meeting ASP 166
111. Ahmad N, Kalka K and Mukhtar H (2001) In vitro and in vivo inhibition of epidermal growth factor receptor-tyrosine kinase pathway by photodynamic therapy. Oncogene 20:2314-2317
112. Wong TW, Tracy E, Oseroff AR and Baumann H (2003) Photodynamic therapy mediates immediate loss of cellular responsiveness to cytokines and growth factors. Cancer Res 63:3812-3818
113. Liu W, Oseroff AR and Baumann H (2004) Photodynamic therapy causes cross-linking of signal transducer and activator of transcription proteins and attenuation of interleukin-6 cytokine responsiveness in epithelial cells. Cancer Res 64:6579-6587
114. del Carmen MG, Rizvi I, Chang Y, Moor AC, Oliva E, Sherwood M, Pogue B and Hasan T (2005) Synergism of epidermal growth factor receptortargeted immunotherapy with photodynamic treatment of ovarian cancer in vivo. J Natl Cancer Inst 97:1516-1524
115. Cengel K, Voong K and Hahn S. Unpublished Observations
116. Mills GB and Moolenaar WH (2003) The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 3:582-591
117. Agarwal R and Kaye SB (2003) Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 3:502-516
118. Yagi H, Miyamoto S, Tanaka Y, Sonoda K, Kobayashi H, Kishikawa T, Iwamoto R, Mekada E and Nakano H (2005) Clinical significance of heparinbinding epidermal growth factor-like growth factor in peritoneal fluid of ovarian cancer. Br J Cancer 92:1737-1745
119. Solban N, Rizvi I and Hasan T (2006) Targeted photodynamic therapy. Lasers Surg Med 38:522-531
120. Molpus KL, Hamblin MR, Rizvi I and Hasan T (2000) Intraperitoneal photoimmunotherapy of ovarian carcinoma xenografts in nude mice using charged photoimmunoconjugates. Gynecol Oncol 76:397-404